[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603878":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":10,"centralContacts":33,"locations":39,"responsibleParty":56,"collaborators":10,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":10,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":10,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":10,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"New Valley University","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"1",null,"Primary APS",[13,14,15],"Diagnostic Test: • Complete blood count , MPV","Diagnostic Test: Calculation of PLR: Platelet count \u002F Lymphocyte count and Calculation of NLR:","Diagnostic Test: Antiphospholipid antibody profile",{"label":17,"type":10,"description":18,"interventionNames":19},"2","secondary APS",[13,14,15],[21,26,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":10},"DIAGNOSTIC_TEST","• Complete blood count , MPV","CBC report",[9,17],{"type":22,"name":27,"description":24,"armGroupLabels":28,"otherNames":10},"Calculation of PLR: Platelet count \u002F Lymphocyte count and Calculation of NLR:",[9,17],{"type":22,"name":30,"description":31,"armGroupLabels":32,"otherNames":10},"Antiphospholipid antibody profile","Patient record",[9,17],[34],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Asmaa Nady Hussein, MD","CONTACT","01065161752","asmaanady_1010@med.nvu.edu.eg",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Al Khārjah","Kharga Oasis","72511","Egypt","EG",{"type":48,"coordinates":49},"Point",[50,51],30.54653,25.45101,{"lat":51,"lon":50},[54],{"name":55,"role":36,"phone":37,"phoneExt":10,"email":38},"Asmaa N Hussein, MD",{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Asmaa Nady Hussein","Lecturer","100603878","hematological-markers-mpv-plr-and-nlr-in-primary-versus-secondary-antiphospholipid-syndrome-100603878",false,"NCT07142239","Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome","Comparative Analysis of Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary Antiphospholipid Syndrome","Inclusion Criteria:\n\n* Adults (age ≥18 years)\n* Diagnosis of APS based on updated Sydney classification criteria confirmed by: Clinical history of thrombosis and\u002For pregnancy morbidity, Persistent presence (≥12 weeks) of antiphospholipid antibodies (aCL, anti-β2-glycoprotein I, and\u002For lupus anticoagulant)\n\nExclusion criteria:\n\n* Current infection or inflammatory condition unrelated to APS\n* Hematological malignancies or other blood disorders\n* Recent blood transfusion or platelet-altering medications other than APS treatments","ALL","18 Years",{"count":70,"type":71},150,"ESTIMATED","OBSERVATIONAL","Antiphospholipid syndrome is a thrombo-inflammatory autoimmune disorder with a complex antiphospholipid antibody-mediated pathogenesis, and high heterogeneity in clinical presentation and disease course. Clinical presentation in antiphospholipid syndrome includes venous and arterial thrombosis, pregnancy complications, and a broad range of microvascular and non-thrombotic manifestations",[75],"Antiphospholipid Syndrome","2026-07-30",{"date":78,"type":79},"2026-07-31","ACTUAL",{"date":81,"type":79},"2025-11-27",{"date":83,"type":71},"2027-06-30",{"name":5,"class":6},1]